Healthcare provider profile · identity verified

Matthew D Hanserd, MD

Allopathic & Osteopathic Physicians|Internal Medicine · ATHENS, AL · NPI 1942524434

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Matthew D Hanserd, MD received $20.58 in general payments during 2025 across 1 reported records.

PFIZER INC. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 526 claims for Eliquis by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$20.58

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
PFIZER INC.	Unresolved — no canonical attribution shown	$20.58	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$20.58	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
ELIQUIS Normalized: eliquis	Drug	PFIZER INC.	$20.58	1	2025
Source payment records 2025-04-15 · PFIZER INC. · $20.58 · Open Payments source
PAXLOVID Normalized: paxlovid	Drug	PFIZER INC.	$20.58	1	2025
Source payment records 2025-04-15 · PFIZER INC. · $20.58 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ELIQUIS eliquis	2025	Eliquis	2024	526	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	526	39

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	1430	53
Pantoprazole Sodium	Pantoprazole Sodium	1339	62
Furosemide	Furosemide	1264	59
Atorvastatin Calcium	Atorvastatin Calcium	1207	46
Potassium Chloride	Potassium Chloride	1193	51
Amlodipine Besylate	Amlodipine Besylate	1072	48
Sertraline Hcl	Sertraline Hcl	1037	46
Lisinopril	Lisinopril	852	29
Buspirone Hcl	Buspirone Hcl	730	35
Omeprazole	Omeprazole	706	34
Trazodone Hcl	Trazodone Hcl	662	32
Mirtazapine	Mirtazapine	615	34
Metoprolol Succinate	Metoprolol Succinate	603	27
Eliquis	Apixaban	526	39
Metformin Hcl	Metformin Hcl	508	19
Famotidine	Famotidine	475	20
Divalproex Sodium	Divalproex Sodium	433	27
Simvastatin	Simvastatin	411	15
Quetiapine Fumarate	Quetiapine Fumarate	406	26
Carvedilol	Carvedilol	395	22
Clopidogrel	Clopidogrel Bisulfate	379	14
Losartan Potassium	Losartan Potassium	376	19
Metoprolol Tartrate	Metoprolol Tartrate	358	15
Escitalopram Oxalate	Escitalopram Oxalate	341	12
Allopurinol	Allopurinol	332	15
Memantine Hcl	Memantine Hcl	318	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	314	61
Pravastatin Sodium	Pravastatin Sodium	301	13
Sucralfate	Sucralfate	282	12
Levetiracetam	Levetiracetam	273	15
Tamsulosin Hcl	Tamsulosin Hcl	270	16
Donepezil Hcl	Donepezil Hcl	259	15
Duloxetine Hcl	Duloxetine Hcl	249	suppressed
Amiodarone Hcl	Amiodarone Hcl	246	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	222	suppressed
Montelukast Sodium	Montelukast Sodium	215	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	203	suppressed
Gabapentin	Gabapentin	197	28
Oxybutynin Chloride Er	Oxybutynin Chloride	192	suppressed
Citalopram Hbr	Citalopram Hydrobromide	187	15
Ondansetron Hcl	Ondansetron Hcl	182	30
Prednisone	Prednisone	178	22
Baclofen	Baclofen	176	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	170	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	165	suppressed
Xarelto	Rivaroxaban	159	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	155	suppressed
Diltiazem Hcl	Diltiazem Hcl	153	suppressed
Methocarbamol	Methocarbamol	153	15
Carbidopa-Levodopa	Carbidopa/Levodopa	148	suppressed
Labetalol Hcl	Labetalol Hcl	145	suppressed
Valproic Acid	Valproic Acid	136	suppressed
Lorazepam	Lorazepam	132	23
Benazepril Hcl	Benazepril Hcl	128	suppressed
Bupropion Xl	Bupropion Hcl	127	suppressed
Olanzapine	Olanzapine	127	suppressed
Clonidine Hcl	Clonidine Hcl	124	12
Risperidone	Risperidone	123	suppressed
Warfarin Sodium	Warfarin Sodium	119	suppressed
Spironolactone	Spironolactone	114	13
Topiramate	Topiramate	114	suppressed
Finasteride	Finasteride	111	suppressed
Meloxicam	Meloxicam	108	suppressed
Jardiance	Empagliflozin	107	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	106	suppressed
Tramadol Hcl	Tramadol Hcl	106	16
Irbesartan	Irbesartan	105	suppressed
Haloperidol	Haloperidol	104	suppressed
Meclizine Hcl	Meclizine Hcl	104	suppressed
Aripiprazole	Aripiprazole	95	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	94	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	91	suppressed
Valsartan	Valsartan	91	suppressed
Enulose	Lactulose	89	suppressed
Lamotrigine	Lamotrigine	88	suppressed
Loxapine	Loxapine Succinate	88	suppressed
Nebivolol Hcl	Nebivolol Hcl	86	suppressed
Digoxin	Digoxin	85	suppressed
Entresto	Sacubitril/Valsartan	82	suppressed
Lovastatin	Lovastatin	82	suppressed
Fluticasone Propionate	Fluticasone Propionate	81	33
Benztropine Mesylate	Benztropine Mesylate	80	suppressed
Oxcarbazepine	Oxcarbazepine	80	suppressed
Carbamazepine	Carbamazepine	76	suppressed
Ceftriaxone	Ceftriaxone Sodium	76	29
Glipizide	Glipizide	76	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	68	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	67	suppressed
Lansoprazole	Lansoprazole	61	suppressed
Januvia	Sitagliptin Phosphate	58	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	57	suppressed
Bupropion Hcl Sr	Bupropion Hcl	57	suppressed
Gemtesa	Vibegron	57	suppressed
Hydralazine Hcl	Hydralazine Hcl	57	suppressed
Flecainide Acetate	Flecainide Acetate	56	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	56	suppressed
Glimepiride	Glimepiride	54	suppressed
Paroxetine Hcl	Paroxetine Hcl	54	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	54	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	53	suppressed
Methimazole	Methimazole	53	suppressed
Alendronate Sodium	Alendronate Sodium	52	suppressed
Carbamazepine Er	Carbamazepine	52	suppressed
Colesevelam Hcl	Colesevelam Hcl	52	suppressed
Enalapril Maleate	Enalapril Maleate	52	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	52	suppressed
Lubiprostone	Lubiprostone	52	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	52	suppressed
Prazosin Hcl	Prazosin Hcl	52	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	52	suppressed
Lithium Carbonate	Lithium Carbonate	51	suppressed
Primidone	Primidone	51	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	51	suppressed
Lidocaine Hcl	Lidocaine Hcl	50	31
Sps	Sodium Polystyrene Sulfon/Sorb	48	suppressed
Latanoprost	Latanoprost	47	11
Ropinirole Hcl	Ropinirole Hcl	45	suppressed
Paliperidone Er	Paliperidone	44	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	42	18
Divalproex Sodium Er	Divalproex Sodium	41	suppressed
Dilantin	Phenytoin Sodium Extended	39	suppressed
Lacosamide	Lacosamide	39	suppressed
Humalog	Insulin Lispro	38	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	38	suppressed
Calcitriol	Calcitriol	37	suppressed
Alprazolam	Alprazolam	35	suppressed
Celecoxib	Celecoxib	35	suppressed
Cholestyramine	Cholestyramine (With Sugar)	35	suppressed
Novolog	Insulin Aspart	35	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	suppressed
Oxycodone Hcl	Oxycodone Hcl	29	suppressed
Diazepam	Diazepam	27	suppressed
Fycompa	Perampanel	26	suppressed
Clonazepam	Clonazepam	25	suppressed
Diltiazem 24hr Er (La)	Diltiazem Hcl	24	suppressed
Verapamil Er	Verapamil Hcl	23	suppressed
Torsemide	Torsemide	22	suppressed
Cyclosporine	Cyclosporine	21	suppressed
Dutasteride	Dutasteride	21	suppressed
Levemir	Insulin Detemir	21	suppressed
Admelog	Insulin Lispro	20	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	20	suppressed
Cephalexin	Cephalexin	20	15
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	20	suppressed
Azithromycin	Azithromycin	19	16
Pregabalin	Pregabalin	19	suppressed
Bethanechol Chloride	Bethanechol Chloride	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Atenolol	Atenolol	17	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	17	suppressed
Santyl	Collagenase Clostridium Hist.	17	16
Trimethoprim	Trimethoprim	17	suppressed
Telmisartan	Telmisartan	16	suppressed
Testosterone Cypionate	Testosterone Cypionate	16	suppressed
Mupirocin	Mupirocin	15	suppressed
Levofloxacin	Levofloxacin	14	13
Terazosin Hcl	Terazosin Hcl	14	suppressed
Albuterol Sulfate	Albuterol Sulfate	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Nystop	Nystatin	13	11
Insulin Lispro	Insulin Lispro	12	suppressed
Lorazepam Intensol	Lorazepam	12	11
Methadone Hcl	Methadone Hcl	12	suppressed
Modafinil	Modafinil	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	suppressed
Rizatriptan	Rizatriptan Benzoate	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Clobazam	Clobazam	11	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Linzess	Linaclotide	11	suppressed
Novolin R	Insulin Regular, Human	11	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	11	suppressed
Sildenafil Citrate	Sildenafil Citrate	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed
Tobramycin-Dexamethasone	Tobramycin/Dexamethasone	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$20.58 · 1 records	PFIZER INC.	ELIQUIS, PAXLOVID	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Eliquis play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error